Building Healthcare AI: FDA Approval, Fundraising, and Practical Tradeoffs from BioticsAI
BioticsAI's founder Robhy Bustami shared the company's experience navigating FDA approvals, fundraising, and team motivation while building in the regulated healthcare space. Their story highlights the unique discipline required to advance clinical AI products from prototype to deployed tool.
Regulation shapes product and timelines. BioticsAI's journey illustrates how regulatory pathways dictate architecture, data strategy, and timelines. Unlike consumer apps, healthcare AI must prioritize clinical validation, explainability, and safety from day one-requirements that lengthen development cycles but are essential for adoption in clinical settings and reimbursement discussions.
Fundraising and team management realities. Investors and founders must reconcile the long horizon of clinical validation with capital needs. BioticsAI's experience shows that clear milestone frameworks (e.g., IRB studies, pilot deployments, FDA submissions) help maintain investor confidence and staff focus. Leadership must balance scientific rigor with pragmatic MVP thinking to deliver incremental value while working toward regulatory milestones.
Practical guidance for business leaders. For organizations entering healthcare AI, prioritize three actions:
- Design regulatory strategy in product planning, not as a later compliance add-on-identify the right FDA pathway early.
- Invest in early clinical partnerships and data governance to accelerate validation and strengthen claims.
- Align investors around milestone-based financing and be transparent about timelines and risk.
Healthcare AI demands discipline, but it also rewards organizations that combine clinical partnerships, robust evidence generation, and pragmatic commercialization planning.
Original Source
TechCrunch